Trials / Completed
CompletedNCT04351334
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Patient Profiles and Treatment Patterns Among ALK-positive NSCLC Patients Treated With Alectinib
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 161 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to understand patient profiles, treatment patterns, and clinical outcomes among ALK-positive NSCLC patients treated with alectinib, and post-alectinib treatment patterns and outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alectinib | Observational treatment based on physician choice |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2020-04-17
- Last updated
- 2024-09-19
- Results posted
- 2024-09-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04351334. Inclusion in this directory is not an endorsement.